A Phase II Study to Evaluate: Delay in Intravaginal Ejaculatory Latency Time (IELT), Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Randomized, Double Blind, Placebo-Controlled, Parallel Group Study in Men with Premature Ejaculation.

Registry ID

EUCTR2009-011855-40

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

GlaxoSmithKline Research and Development Ltd

Start date

2009-10-20

Last update

2026-08-16

Conditions

• Premature ejaculation.

Summary

To determine if an on demand dosing of 50 or 150 mg of GSK557296 demonstrates superior efficacy with respect to duration of IELT during an 8 week study period compared to placebo in men with premature ejaculation.

Locations

• , , Netherlands

View on source registry